Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Publikation

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Wissenschaftlicher Artikel/Review - 14.05.2011

Joly Florence, Huober Jens, Dell'Anna Tiziana, Ferrandina Gabriella, Vergote Ignace, Reinthaller Alexander, Vaughan Michelle, Sugimoto Akira, Boman Karin, Donoghoe Mark, Fabbro Michel, Ray-Coquard Isabelle, Pujade-Lauraine Eric

Zitation

Joly F, Huober J, Dell'Anna T, Ferrandina G, Vergote I, Reinthaller A, Vaughan M, Sugimoto A, Boman K, Donoghoe M, Fabbro M, Ray-Coquard I, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226-32.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Gynecol Oncol 2011; 122

Veröffentlichungsdatum

14.05.2011

eISSN (Online)

1095-6859

Seiten

226-32

Kurzbeschreibung/Zielsetzung

To describe and analyze observed hypersensitivity reactions (HSR) from the randomized, multicenter phase III CALYPSO trial that evaluated the efficacy and safety of the combination of carboplatin and pegylated liposomal doxorubicin (CD) compared with standard carboplatin-paclitaxel (CP) in patients with platinum-sensitive relapsed ovarian cancer (ROC).